Last reviewed · How we verify
treatment with brimonidine/timolol
Brimonidine is an alpha-2 adrenergic agonist and timolol is a non-selective beta-blocker; together they reduce intraocular pressure through different pathways to treat glaucoma.
Brimonidine is an alpha-2 adrenergic agonist and timolol is a non-selective beta-blocker; together they reduce intraocular pressure through different pathways to treat glaucoma. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | treatment with brimonidine/timolol |
|---|---|
| Sponsor | Aristotle University Of Thessaloniki |
| Drug class | Alpha-2 adrenergic agonist / Beta-blocker combination |
| Target | Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Brimonidine stimulates alpha-2 adrenergic receptors to decrease aqueous humor production and increase uveoscleral outflow. Timolol blocks beta-adrenergic receptors to reduce aqueous humor production. The combination provides additive intraocular pressure-lowering effects with complementary mechanisms of action.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Ocular hyperemia
- Eye irritation
- Dry eye
- Blurred vision
- Allergic conjunctivitis
Key clinical trials
- Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
- PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) (PHASE3)
- Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma (PHASE4)
- Efficacy and Necessity of Time Interval Between Instillation of Two Glaucoma Eye Drops (NA)
- 24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol (PHASE4)
- Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno® (PHASE1)
- Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK) (PHASE3)
- Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: